KD019 Versus Erlotinib in Subjects With Stage IIIB/IV Non Small Cell Lung Cancer With Progression After First- or Second-Line Chemotherapy
What is the purpose of this trial?
This is a research study designed to look at the effects of an investigational chemotherapy drug, KD019, on non small cell lung cancer in comparison to a standard chemotherapy drug, Erlotinib ( Tarceva®).
- 18 Years and older
- Kadmon Corporation, LLC
- Last Updated:
- Study HIC#: